Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Gastric Cancer


Se Jun Park


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


S.J. Park1, I. Kim2, J. Lee3, H. Kim1, K. Shin1

Author affiliations

  • 1 Department Of Internal Medicine, Seoul St. Mary's Hospital, of the Catholic University, 137-701 - Seoul/KR
  • 2 Department Of Internal Medicine, Seoul St. Mary's Hospital, Seoul/KR
  • 3 Department Of Internal Medicine, Division Of Medical Oncology, Seoul St. Mary's Hospital, of the Catholic University, 137-701 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3769


Lymphocytes are an important portion of the cell-mediated immune system, and play a significant role in immune responses to cancer. We investigated whether peripheral lymphocyte are associated with disease-free survival, gastric cancer-specific survival, and overall survival in surgically resected gastric cancer.


We retrospectively evaluated stage II-III gastric cancer patients who underwent curative surgical resection to analyze correlations among absolute lymphocyte counts and prognosis. Multivariable regression models adjusted for age, performance status, cancer stage, neoadjuvant/adjuvant chemotherapy use, HER2 expression were used to evaluate associations between absolute lymphocyte count, disease-free survival, gastric cancer-specific overall survival, and overall survival.


A total of 338 stage II-III gastric cancer patients were diagnosed from January 2011 to December 2015. At the time of diagnosis, lymphopenic were 31 (9.1%) and no patients were neutropenic. Nearly one quarter (25.1%) were ever neutropenic (ANC <1.0 K/μL) and nearly half (52.6%) were lymphopenic (ALC <1.0 K/μL) with a mean minimum ALC value of 1.00 K/μL. On multivariable analysis, ever lymphopenia predicted higher recurrence rate [HR = 12.4; 95% CI 4.9-31.3], higher gastric cancer-specific mortality [HR = 22.7; 95% CI 6.5-79.1], and higher overall mortality [HR = 36.6; 95% CI 10.3-130.0]. Five year disease-free survival was 57% for patients who were ever lymphopenic versus 96% for those who were not. Fiver year gastric cancer specific overall survival was 65% versus 98% for ever lymphopenic and never lymphopenic patients, respectively.


Higher peripheral lymphocyte counts predicted lower recurrence rate and better overall survival from potentially curable gastric cancer, suggesting that immune function may enhance the effectiveness of non-advanced gastric cancer treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.